Signatera for detecting molecular residual disease from solid tumour cancers

Equality considerations

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others.

No equality issues were identified related to the use of Signatera. Cancer is considered a disability under the Equality Act 2010. Incidence rates in the UK for all cancers combined are highest in people aged 85 to 89 with more than a third of diagnoses each year being in people aged 75 and older. Age and disability are protected characteristics under the Equality Act 2010.